Observational studyScience advances2025

Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome.

Jessica C Hargarten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.